| Literature DB >> 26701651 |
Abdelfattah El Ouaamari1, Ercument Dirice1, Nicholas Gedeon1, Jiang Hu1, Jian-Ying Zhou2, Jun Shirakawa1, Lifei Hou3, Jessica Goodman4, Christos Karampelias5, Guifeng Qiang6, Jeremie Boucher7, Rachael Martinez1, Marina A Gritsenko2, Dario F De Jesus1, Sevim Kahraman1, Shweta Bhatt1, Richard D Smith2, Hans-Dietmar Beer8, Prapaporn Jungtrakoon9, Yanping Gong4, Allison B Goldfine10, Chong Wee Liew6, Alessandro Doria9, Olov Andersson5, Wei-Jun Qian2, Eileen Remold-O'Donnell11, Rohit N Kulkarni12.
Abstract
Although compensatory islet hyperplasia in response to insulin resistance is a recognized feature in diabetes, the factor(s) that promote β cell proliferation have been elusive. We previously reported that the liver is a source for such factors in the liver insulin receptor knockout (LIRKO) mouse, an insulin resistance model that manifests islet hyperplasia. Using proteomics we show that serpinB1, a protease inhibitor, which is abundant in the hepatocyte secretome and sera derived from LIRKO mice, is the liver-derived secretory protein that regulates β cell proliferation in humans, mice, and zebrafish. Small-molecule compounds, that partially mimic serpinB1 effects of inhibiting elastase activity, enhanced proliferation of β cells, and mice lacking serpinB1 exhibit attenuated β cell compensation in response to insulin resistance. Finally, SerpinB1 treatment of islets modulated proteins in growth/survival pathways. Together, these data implicate serpinB1 as an endogenous protein that can potentially be harnessed to enhance functional β cell mass in patients with diabetes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26701651 PMCID: PMC4715773 DOI: 10.1016/j.cmet.2015.12.001
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287